Egyptian Drug Authority Approves Biomerica's Full Portfolio of Rapid Screening Tests

Reuters
2025/12/11
Egyptian Drug Authority Approves Biomerica's Full Portfolio of Rapid Screening Tests

Biomerica Inc. has received authorization from the Egyptian Drug Authority (EDA) for its complete portfolio of rapid screening tests. The approval allows Biomerica to market and distribute its at-home tests for colorectal disease, breast self-exam, prostate disease, kidney disease, and H. pylori infection throughout Egypt. These rapid, easy-to-use, and cost-effective tests are designed for early detection of cancers and chronic diseases, supporting both individual and mass population screenings. The authorization is expected to strengthen preventive healthcare efforts and expand Biomerica's presence in the Middle East and North Africa region. No grants or funding involving other organizations were mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600581) on December 11, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10